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Major advances have been made in the last decade on the molecular
pathogenesis of cancers. Activation of oncogenes and inactivation of
tumour suppressor genes have been elucidated in many forms of
cancers, opening up a map of molecular pathways leading to
unchecked cellular proliferation, impaired apoptosis and failure of
cellular differentiation, and hence cancer formation. Oncogenes are
usually activated by a gain-of-function mutation, while tumour
suppressor genes are inactivated by a loss-of-function mutation.
(Figure 1)
For instance, some haematological cancers are initiated by
chromosomal translocation leading to activation of oncogenes. An
example is the constitutive activation of cytosolic tyrosine kinase
ABL by a chromosomal translocation t(9;22) in chronic myeloid
leukaemia (CML), which is the basis of success of tyrosine kinase
inhibitors in CML. On the other hand, Epidermal Growth Factor
(EGF) (the ligand) and its cognate receptor, EGF Receptor (EGFR),
together with the receptor-associated tyrosine kinase, constitute a
system of utmost importance in the pathogenesis of most cancers of
epithelial origin. Moreover, while haematological cancers naturally
spread by the bloodstream, solid cancers spread by local lymphatics
to regional lymph nodes before invasion of the blood stream and
hence distant metastasis. Therefore, while there are similarities
between haemic and solid cancers, there are also genetic alterations
that are specific to solid or haematological cancers.
Recently aberrant gene promoter methylation has been shown to
result in gene silencing, and hence serves as an alternative mode of
gene inactivation. Indeed, some tumour suppressor genes involved
in the regulation of the cell cycle (CDKN2A and B), genes protecting
cells from oncogenic transformation (P14, DAP kinase) and genes
important in cellular differentiation (soluble Wnt inhibitors) have
been shown to be inactivated by gene promoter hypermethylation.
(Figure 2) In MDS, CDKN2B (alias p15) is hypermethylated and
silenced. Interestingly, unlike gene mutation, which is irreversible,
gene hypermethylation can be reversed with hypomethylating
agents such as Vidaza or Decitabine. Indeed, both Vidaza and
Decitabine have been shown to be effective in MDS.
With the knowledge of these molecular pathways, one will envisage
that either therapeutic antibodies or small molecules that target the
EGFR or the receptor-associated tyrosine kinase will lead to
downregulation of growth and survival signals in the cancer cell,
and hence apoptosis of the cancer cells. After the first success from
rituximab in B-cell lymphomas and imatinib in CML, there is a
massive explosion of both therapeutic antibodies and small
molecules in solid cancers. The antibodies include bevacizumab
(Avastin) in both breast and colon cancer, trastuzumab (Herceptin)
in breast cancer and Cetuximab (Erbitux) in colon cancer targeting
VEGF, HER2 and EGFR respectively. Therefore, these antibodies
target angiogenesis or cellular proliferation associated with growth
Dr. PDr. James CS Chim 
Editor
Dr. James CS Chim 
Demethylation Therapy 
in Haemic Cancer
Published by
The Federation of Medical Societies of Hong Kong
EDITOR-IN-CHIEF
Dr. MOK Chun-on
莫鎮安醫生
EDITORS
Dr. CHAN Chi-fung, Godfrey
陳志峰醫生   (Paediatrics)
Dr. CHAN Chun-hon, Edmond
陳振漢醫生 (General Practice)
Dr. KING Wing-keung, Walter
金永強醫生 (Plastic Surgery)
Dr. YU Kong-san
俞江山醫生   (Orthopaedics & Traumatology)
EDITORIAL BOARD
Dr. CHAN Chi-wai, Angus
陳志偉醫生   (General Surgery)
Dr. Norman CHAN
陳諾醫生 (Diabetes, Endocrinology & Metabolism)
Dr. CHIANG Chung-seung
蔣忠想醫生  (Cardiology)
Dr. CHIM Chor-sang,James
詹楚生醫生 (Haematology)
Dr. CHONG Lai-yin
莊禮賢醫生   (Dermatology & Venereology)
Dr. FAN Yiu-wah
范耀華醫生   (Neurosurgery)
Dr. FOO Wai-lum, William
傅惠霖醫生   (Oncology)
Dr. FONG Ka-yeung
方嘉揚醫生  (Neurology)
Dr. Fung Ho-chuen, Alec
馮浩泉醫生 (Dermatology & Venereology)
Prof. HO Pak-leung
何　良醫生   (Microbiology)
Dr. KWOK Po-yin, Samuel
郭寶賢醫生  (General Surgery)
Dr. LAI Kei-wai, Christopher
賴奇偉醫生   (Respiratory Medicine)
Dr. LAI Sik-to, Thomas
黎錫滔醫生  (Gastroenterology & Hepatology)
Dr. LAI Yuk-yau, Timothy
賴旭佑醫生  (Ophthalmology)
Dr. LAM Tat-chung, Paul
林達聰醫生 (Psychiatry)
Dr. LAM Wai-man, Wendy
林慧文醫生  (Radiology)
Dr. LEE Man-piu, Albert
李文彪醫生   (Dentistry)
Dr. Richard K. LO
羅光彥醫生   (Urology)
Dr. LO See-kit, Raymond
勞思傑醫生   (Geriatric Medicine)
Dr. MAN Chi-wai
文志偉醫生   (Urology)
Dr. MOK, Mo-yin
莫慕賢醫生 (Rheumatology)
Dr. TSANG Wai-kay
曾偉基醫生   (Nephrology)
Dr. TSE Tak-fu
謝德富醫生   (Cardiology)
Prof. WEI I, William
韋霖醫生   (Otorhinolaryngology)
Dr. WONG Bun-lap, Bernard
黃品立醫生   (Cardiology)
Design and Production
VOL.11 NO.5 MAY 2006 Medical Bulletin
3
L. 3 NO.8 UGUST 2008
receptor-mediated cell signaling. On the other hand,
small molecules targeting receptor-associated tyrosine
kinase or multiple kinases are also found to be
effective in multiple solid cancers, which include
Gefitinib (Iressa) and Erlotinib (Tarceva) in
bronchogenic cacrcinoma, sorafenib in renal cell and
recently hepatocellular carcinoma, and sunitinib in
renal cell cancers. In particular, synergistic effect may
be derived when conventional chemotherapy is
combined with some of these targeted therapies.
Therefore, advances in cancer therapy is evolving with
high-speed in recent years.
On the other hand, another important advance is made
in the advent of more potent anti-fungal therapeutic
agents. Treatment of acute leukaemia is often
complicated with prolonged neutropenia leading to
invasive fungal infections such as pulmonary
aspergillosis or invasive candidiasis. The development
of these fungal infections poses major difficulty to
further intensive chemotherapy, leading to suboptimal
treatment. Conventional treatment with amphotericin
B is effective, but is associated with frequent side-
effects like infusion toxicities and renal impairment.
The advent of new anti-fungal agents including
liposomal amphotericin B, caspofungin, voriconazole
and recently posaconazole is important as they have a
broad-spectrum of anti-fungal activity and can be used
even in the presence of renal impairment in contrast to
conventional amphotericin B, in which the dose has to
be reduced.
Therefore, in the field of solid and haematological
cancers, major advances have been made. In this issue
of the Medical Diary, the advances of targeted therapy
in breast, lung and liver cancers, the use of
hypomethylating agents in MDS, and new anti-fungal
agents are discussed.
Figure 1 illustrated the mechanism of carcinogenesis. Normally
tumour suppressor genes will be activated if oncogenic
transformation is detected in the cell. (Upper panel) Therefore,
cancer formation usually results from activation of oncogenes
together with inactivation of tumour suppressor genes.
Figure 1 illustrated the mechanism of carcinogenesis. Normally
tumour suppressor genes will be activated if oncogenic
transformation is detected in the cell. (Upper panel) Therefore,
cancer formation usually results from activation of oncogenes
together with inactivation of tumour suppressor genes.
Members' Benefits
The Federation of Medical Societies of Hong Kong
We are pleased to announce a new benefit for our members. The Federation, in
cooperation with Kingsway Concept Limited, will offer a discount on petrol and
diesel purchases of HK$0.9/litre from Caltex, Shell, Esso and Sinopec to members
and their families of all Ordinary and Associate member societies under the
Federation. Please contact our Secretariat at 2527 8898 and info@fmshk.org or
Kingsway Concept Limited at 2541 1828 and kingswayconcept@yahoo.com for further
details and terms for this offer.

VOL.11 NO.5 MAY 2006 Medical Bulletin
5
L. 3 NO.8 UGUST 2008
Myelodysplastic Syndrome
Myelodysplastic Syndrome (MDS) is a group of clonal
stem cell disorders with ineffective haematopoiesis of the
bone marrow.1-2 Clinically MDS is characterised by
peripheral cytopenia with a hypercellular and dysplastic
bone marrow. Patients usually presents with
complications of cytopenia including symptomatic
anaemia, bleeding from thrombocytopenia or infections
from neutropenia. MDS comprises a group of disorders
with variable cytopenia and a variable amount of
myeloblasts, and hence a variable risk of leukaemic
transformation. In French-American-British (FAB)
classification,3 MDS comprises 5 disorders based on the
severity of cellular dysplasia, the nature of erythroid
dysplasia, the amount of blast cells and presence of
monocytes including refractory anaemia (RA), refractory
anaemia with ringed sideroblasts (RARS), chronic
myelomonocytic anaemia (CMML), refractory anaemia
with excess blasts (RAEB) and refractory anaemia with
excess blasts in transformation (RAEB-t).3 Frequent
karyotypic aberrations include chromosomal loss such
del(5q) or 5q-, del(7q) 7q- or chromosomal gain such as
trisomy 8. In general, normal karyotype or 5q- are
associated with good prognosis while complex
karyotypic abnormality and chromosomal loss of 7q-
with poor prognosis. Moreover, based on the amount of
blasts, severity of cytopenia and the type of chromosomal
aberration, patients with MDS can be stratified into
different risk groups by the International Prognostic
Scoring System (Table 1).4 In general, based on the
median survivals, MDS can be classified into high-risk or
low-risk with median survivals <5 or >5 years. High-risk
MDS include RAEB and RAEB-t and low-risk MDS
includes RA or RARS. (Figure 1)
Treatment may be directed towards killing the blasts by
conventional chemotherapy (such as cytarabine and
daunorubicin used in acute myeloid leukaemia) or
ameliorating the pancytopenia by cytokine therapy such
G-CSF or erythropoietin. However, the only modality of
treatment that may render a cure is bone marrow
transplantation (BMT) in the form of high-dose therapy
with allogeneic haematopoietic stem cell rescue (allo-
BMT). Recently, the advent of non-myeloablative
allogeneic BMT or mini-allo-BMT has allowed more
elderly MDS patients to receive BMT.5 On the other hand,
certain MDS subtypes may benefit from other therapies.
For instance, patients with sideroblastic anaemia may
respond to high-dose of pyridoxine and patients with
hypoplastic MDS may respond to immunosuppressive
therapy such as cyclosporine A or anti-thymocyte
globulin (ATG.).5 A special syndrome of MDS, 5q-
syndrome, in which 5q- is the sole cytogenetic aberration,
is characterised by refractory anaemia with
thrombocytosis in a middle or old-aged female.6
Interestingly, patients with 5q- syndrome respond
favourably to an immunomodulatory agent,
lenalidomide, which is a derivative of thalidomide.
However, 5q- syndrome is an uncommon subtype
amongst MDS. Despite the large number of treatment
options, the majority including conventional
chemotherapy are largely palliative, and do not lead to a
cure. Indeed, the majority of the current treatments may
result in improvement in blood counts but do not alter
the natural history of the disease especially leukaemic
transformation. Moreover, while allogeneic BMT is
potentially curative, only young patients with an HLA-
identical sibling can be considered because of the
inherent risk of graft-versus-host disease and infective
complications, and hence is not applicable to the majority
of elderly MDS patients.7 Therefore, an alternative
treatment strategy especially one that may reduce the
risk of leukaemic transformation is urgently needed.
DNA Methylation
D N A m e t h y l a t i o n , c a t a l y s e d b y D N A
methyltransferase, involves the addition of a methyl
group to the carbon 5 position of the cytosine ring in the
CpG dinucleotide and results in the generation of
methylcytosine.8,9 (Figure 2) Methylation of cytosine to
methylcytosine in DNA is a heritable genetic alteration
during cell replication in the absence of any change in
the genetic sequence. In the normal mammalian
genome, CpG rich regions (CpG islands) exist and these
are often found within the promoter of genes. These
promoter-associated CpG islands that serve as gene
promoters in about 40%-50% of human genes are
protected from methylation, rendering these genes a
transcription-ready state.8,9 The only exceptions are the
promoters of selectively silenced alleles in imprinted
autosomal genes, and the gene promoters of the
inactivated X-chromosome of females. By contrast, CpG
islands of various genes have been shown to be
Epigenetic Therapy Comes of Age: Waking Up
Silenced Tumour Suppressor Genes in
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aberrantly methylated (hypermethylated) in cancer.
Importantly, hypermethylation of gene promoters has
been shown to result in repression of gene transcription
and gene silencing, thus serving as an alternative
mechanism of gene inactivation. The mechanism of
gene silencing has recently been shown to be related to
the recruitment of repressor protein complex containing
histone deacetylase and other repressor proteins such as
methyl-cytosine binding protein (MBP), resulting in de-
acetylation of histone covered by the hypermethylated
promoter DNA. This results in a closed chromatin
structure that precludes access of the active
transcription complex and hence gene silencing.
However, the mechanism of these de novo gene
promoter hypermethylation is largely unknown, and is
the topic of intensive research.
Promoter Hypermethylation in Haemic
Malignancies
In haemic malignancies, methylation of tumour
suppressor genes including CDKN2B (alisas P15),
CDKN2A (alias, P16), P73, DAP kinase, SHP1 has been
reported in various haematological malignancies.9-19
These genes either regulate progression of the cell cycle
(CDKN2A and B), and hence cellular proliferation, the
induction of apoptosis upon detection of oncogeneic
transformation (P14, P73 and DAP kinase) or
intracellular JAK/STAT signalling such as SHP1.9-19 For
instance, P15 but not P16 is frequently methylated in
acute leukaemia but both P15 and P16 are frequently
methylated in NHL, MM and CLL. SHP1 is frequently
methylated in literally all types of haemic cancers but
p73 only methylated in Burkitts' lymphoma. Therefore,
there is heterogeneity in the profile of gene methylation
in different types of haemic malignancies. Importantly,
re-expression of these genes has been shown in vitro by
5-AzaCytidine treatment to result in growth inhibition
and/or apoptosis. Moreover, the high frequency of
methylation of certain genes in some haemic
malignancies suggests that gene hypermethylations are
probably early events in the pathogenesis of these
cancers. For instance, P15 is methylated in >70% of
acute leukaemia including APL, which carries the PML-
RARA fusion gene, suggesting p15 gene methylation
might collaborate with t(15;17) in leukaemogenesis.15
Similarly, in mantle cell lymphoma with upregulation
of cyclin D1, SHP1 has been shown to be methylated in
>80% of cases, suggesting that SHP1 methylation might
be an early event collaboration with cyclin D1
dysregulation in lymphomogenesis. On the other hand,
methylation of some genes is associated with disease
progression, e.g. P16 methylation at relapse but not
diagnosis in acute leukaemia,16 and Abl methylation
during progression to accelerated phase or blastic
transformation in CML. Furthermore, certain
methylated genes are associated with prognosis and
survival. For instance, P15 methylation was shown to
confer an inferior DFS in APL.13,15,18 Therefore, aberrant
gene promoter methylation is potentially important in
either pathogenesis, progression and prognosis.
Therefore, treatments which may reverse these
methylation alterations are potentially beneficial in
haematological cancers. 
Therapeutic DNA Methyltransferase
Inhibitors
In clinical practice, two cytidine analogues, azacytidine
(5-azacytidine; Vidaza Pharmion, USA) and Decitabine
(5-aza-2'-deoxycytidine; DCB, Decogen, SuperGen,
USA), have been shown to carry hypomethylating
properties by inhibiting DNA methyltransferase.20 In
cancers, inhibition of DNA methylation reactivates the
expression of tumour suppressor genes that have
undergone epigenetic silencing, and leads to apoptosis
of cancer cells. 
In MDS, CDKN2B (alias, P15), a cyclin-dependent
kinase inhibitor that negatively regulates the cell cycle
and hence cellular proliferation, has been shown to be
hypermethylated in marrow stem (CD34+) cells in
patients with MDS,21 and is potentially important in its
pathogenesis. Therefore, clinical trials have been
conducted to test the efficacy of these DNA
methyltransferase (DNMT) inhibitors in MDS, and
hence the concept of hypomethylating therapy. At
present both Vidaza and Decitabine are approved for
the treatment of MDS. 
Vidaza in MDS
After promising results from 2 phase II studies by the
CALGB in patients with RAEB, RAEB-T and CMML, a
phase III study using Vidaza in the treatment of MDS
has been published in 2002.22 Recently, data from a
phase III Cancer and Leukaemia Group B (CALGB)
9221 study led to the approval of Vidaza by the US
Food & Drug Administration (FDA). In the study, MDS
patients were randomised to receive Vidaza and best
supportive care. Vidaza was given subcutaneously at
the dose of 75mg/d x 7 days at 28-day cycles. Moreover,
patients in the BSC arm in whom the disease progressed
might cross-over to receive Vidaza after 4 months.
Responses (complete, partial or haematological
improvement) were assessed after 4 cycles of treatment.
Patients in complete remission would receive 3 further
cycles of Vidaza treatment. 191 patients were recruited.
There was a significant improvement in overall
response in the Vidaza arm compared with the BSC arm
(ORR 60% Vidaza arm versus 5% BSC arm, p<0.001).
Complete and partial remissions occurred only in the
Vidaza but not the BSC arm. The frequency of
leukaemic transformation was also significantly
reduced in the Vidaza arm (15% versus 38%). Because
of the cross-over nature of the study, a landmark study
was conducted to assess the impact of Vidaza treatment
on survival, which showed median survival of 18 and 6
months in the Vidaza and BSC arms (p=0.03). Moreover,
the improved survival was associated with an
improvement in the quality of life. 
Decitabine in MDS
On the other hand, phase I/II studies of decitabine
(DCB) in high-grade MDS has also been conducted.23
O'Brien et al showed that in 52 patients with high-grade
MDS, an overall response was observed in 81% of
patients with 35% CR rate. Wijermans et al showed that
in 66 patients with intermediate- to high-grade MDS,
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DCB (at 45mg/m2/d x 3 days every 6 weeks), overall
response rate was 49% with 20% being CR.23 These
encouraging data confirmed the efficacy of DCB in
MDS, which accumulated to a phase III study where
170 patients with MDS were randomised to receive low-
dose DCB (15mg/m2 every 8 hourly x 3 days, repeated
every 6 weeks) or best supportive care (BSC).24 The
study showed a superior overall response rate of 30%
(with 9% CR) in the decitabine arm compared with 7%
(no CR or PR) in the BSC arm (p<.001). There was a non-
significant delay in leukaemic transformation (time to
leukaemia was 12 months in the decitabine arm and 8
months in the BCS arm) but a significant delay in those
with high-risk MDS. Moreover, patients treated with
decitabine had improved quality of life, and cytogenetic
remission was shown in some cases. However, there
was no difference in overall survival.24 On the other
hand, comparison with a historical control group of
high-grade MDS patients treated with conventional
chemotherapy, who were matched in age, sex,
cytogenetic findings and international prognostic
scoring system with 115 MDS patients treated with low-
dose decitabine, showed that there was an obvious
overall survival advantage in high-grade MDS patients
receiving decitabine (median overall survival: 22
months versus 12 months, p<0.001).25 Therefore,
possible survival advantages may be detected in future
prospective trials. Moreover, there are recent data that
patients who progressed or failed to respond to Vidaza
did respond to decitabine.26
Common Features in Both DNMT
Inhibitor Trials
First, a response was only demonstrated after several
cycles of treatment. Therefore, had the patients been
considered non-responding and taken off study after 2
cycles, the response would not have been captured. For
instance, the median time to response was > 3 cycles in
the CALGB9221 trial, and >2 cycles in the Decitabine
trial. Only CR or PR occurred in the DNMT inhibitor
arm while only soft end-point such as haematological
improvement could occur in the best supportive care
arm. Both studies were associated with improved QOL
in patients receiving DNMT inhibitors. Moreover, delay
in leukaemia transformation was observed in the
Vidaza trial,22 and in the subgroup of high-risk MDS in
the Decitabine trial.24 Major side-effects from these
DNMT inhibitors (Vidaza & decitabine) were
worsening cytopenia. 
Future
Vidaza can be administered in an out-patient setting,
and has been shown to be effective in all MDS subtypes,
and results in delay of leukaemic transformation, and
likely improvement in overall survival. Decitabine is an
alternative to Vidaza but impact on survival remains to
be seen in further analysis of the phase III study. 
On the other hand, from the mechanistic point of view,
gene silencing from promoter hypermethylation is
enhanced by further modification of histone molecules,
primarily deacetylation of the regional histone
molecules, where the stretch of hypermethylated
promoter DNA covers. Therefore, one would anticipate
a synergistic effect if histone decaetylase inhibitors are
added to these DNMT inhibitors so that both DNA
methylation and histone deacetylation are reversed, and
hence render an open chromatin in the promoter
concerned, and allow access of transcription complex to
the gene promoter. Indeed, clinical trials incorporating
both DNMT inhibitors and histone deacetylase inhibitors
are on-going, and the results are eagerly awaited.
The advent of the hypomethylating treatment in MDS is
important in the following ways. First, MDS is a disease
of the elderly who generally cannot tolerate intensive
chemotherapy, and hence demethylating therapy is
particularly appealing as they do not mediate their
activity by cytotoxicity. Second, unlike mutations in
cancers, which are irreversible, gene promoter
hypermethylation is a reversible process, and hence is an
important modality of therapy to the treatment of cancers.
Table 1.
Figure 1. shows the different overall survivals in MDS patients with
different FAB subtypes (upper panel), and IPSS risk-groups (lower
panel). The figure is adapted from the paper by Greenberg et al,
Blood, 1998.
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Figure 2. shows the binding of the promoter-asociated CpG island
by a transcription complex in unmethylated promoter, but the
exclusion of transcription complex in a promoter that is aberrantly
methylated
Heaney ML, Golde DW. Myelodysplasia. N Engl J Med, 1999;
340(21): 1649-60.
Peter L. Greenberg, Neal S. Young, and Norbert Gattermann.
Myelodysplastic Syndromes. Hematology, 2002 Jan; 2002: 136 -
161.
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA,
Gralnick HR, Sultan C. Proposals for the classification of the
myelodysplastic syndromes. Br J Haematol, 1982; 51(2): 189-99.
Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G,
Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama
K, Aul C, Mufti G, Bennett J. International scoring system for
evaluating prognosis in myelodysplastic syndromes. Blood, 1997;
89(6): 2079-88.
Deeg HJ, Jiang PY, Holmberg LA, Scott B, Petersdorf EW,
Appelbaum FR. Hematologic responses of patients with MDS to
antithymocyte globulin plus etanercept correlate with improved
flow scores of marrow cells. Leuk Res, 2004; 28(11): 1177-80.
List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E,
Powell B, Greenberg P, Thomas D, Stone R, Reeder C, Wride K,
Patin J, Schmidt M, Zeldis J, Knight R. Myelodysplastic
Syndrome-003 Study Investigators. Lenalidomide in the
myelodysplastic syndrome with chromosome 5q deletion. N Engl
J Med, 2006; 355(14): 1456-65. 
Scott BL, Sandmaier BM, Storer B, Maris MB, Sorror ML,
Maloney DG, Chauncey TR, Storb R, Deeg HJ. Myeloablative vs
nonmyeloablative allogeneic transplantation for patients with
myelodysplastic syndrome or acute myelogenous leukemia with
multilineage dysplasia: a retrospective analysis. Leukemia, 2006
Jan; 20(1): 128-35.
Herman JG, Baylin SB. Gene silencing in cancer in association
with promoter hypermethylation. N Engl J Med, 2003; 349(21):
2042-54.
Chim CS, Liang R, Kwong YL. Gene promoter hypermethylation
in hematologic malignancies. Hematol Oncol, 2002; 20: 167-76.
1.
2.
3.
4.
5.
6.
7.
8.
9.
Chim CS, Fung TK, Liang R. Disruption of INK4/CDK/Rb cell
cycle pathway by gene hypermethylation in multiple myeloma
and MGUS. Leukemia, 2003; 17(12): 2533-5.
Chim CS, Chan WWL, Kwong YL. Epigenetic dysregulation of
the DAP kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in
acute leukaemias. J Clin Pathol, in press, 2008
Chim CS, Fung TK, Wong KF, Lau JS, Law M, Liang R.
Methylation of INK4 and CIP/KIP families of cyclin-dependent
kinase inhibitor in chronic lymphocytic leukaemia in Chinese
patients. J Clin Pathol, 2006 Sep;59(9): 921-6. 
Chim CS, Kwong YL. Adverse prognostic impact of CDKN2B
hyper-methylation in acute promyelocytic leukemia. Leuk
Lymphoma, 2006 May; 47(5): 815-25.
Chim CS, Lau JS, Wong KF, Kwong YL. CDKN2B methylation is
an independent poor prognostic factor in newly diagnosed acute
promyelocytic leukemia. Leukemia, 2006; 20(1): 149-51.
Chim CS, Liang R, Tam CY, Kwong YL. Methylation of p15 and
p16 genes in acute promyelocytic leukemia: potential diagnostic
and prognostic significance. J Clin Oncol, 2001; 19(7): 2033-40.
Chim CS, Tam CY, Liang R, Kwong YL. Methylation of p15 and
p16 genes in adult acute leukemia: lack of prognostic
significance. Cancer, 2001; 91(12): 2222-9.
Chim CS, Wong AS, Kwong YL. Epigenetic inactivation of the
CIP/KIP cell-cycle control pathway in acute leukemias. Am J
Hematol, 2005; 80(4): 282-7.
Chim CS, Wong SY, Kwong YL. Aberrant gene promoter
methylation in acute promyelocytic leukaemia: profile and
prognostic significance. Br J Haematol, 2003; 22(4): 571-8.
Chim CS, Wong SY, Pang A, Chu P, Lau JS, Wong KF, Kwong
YL. Aberrant promoter methylation of the retinoic acid receptor
alpha gene in acute promyelocytic leukemia. Leukemia, 2005 Dec;
19(12): 2241-6. 
Silverman LR, Mufti GJ. Methylation inhibitor therapy in the
treatment of myelodysplastic syndrome. Nat Clin Pract Oncol,
2005 Dec; 2 Suppl 1:S12-23.
Quesnel B, Guillerm G, Vereecque R, Wattel E, Preudhomme C,
Bauters F, Vanrumbeke M, Fenaux P. Methylation of the
p15(INK4b) gene in myelodysplastic syndromes is frequent and
acquired during disease progression. Blood, 1998; 91(8): 2985-90.
Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland
JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL,
DeCastro CM, Ellerton J, Larson RA, Schiffer CA, Holland JF.
Randomized controlled trial of azacitidine in patients with the
myelodysplastic syndrome: a study of the cancer and leukemia
group B. J Clin Oncol, 2002 May 15;20(10): 2429-40.
Kantarjian HM. Recent experience with decitabine in MDS. Clin
Adv Hematol Oncol, 2007 Feb; 5(2): 140.
Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M,
DiPersio J, Klimek V, Slack J, de Castro C, Ravandi F, Helmer R
3rd, Shen L, Nimer SD, Leavitt R, Raza A, Saba H. Decitabine
improves patient outcomes in myelodysplastic syndromes:
results of a phase III randomized study. Cancer, 2006 Apr 15;
106(8): 1794-803.
Kantarjian HM, O'Brien S, Huang X, Garcia-Manero G, Ravandi
F, Cortes J, Shan J, Davisson J, Bueso-Ramos CE, Issa JP. Survival
advantage with decitabine versus intensive chemotherapy in
patients with higher risk myelodysplastic syndrome: comparison
with historical experience. Cancer, 2007 Mar 15; 109(6): 1133-7. 
Borthakur G, Ahdab SE, Ravandi F, Faderl S, Ferrajoli A,
Newman B, Issa JP, Kantarjian H. Activity of decitabine in
patients with myelodysplastic syndrome previously treated with
azacitidine. Leuk Lymphoma, 2008 Apr; 49(4): 690-5.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
References
MCHK CME Programme Self-assessment Questions
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Myelodysplastic Syndrome" by Dr. James CS Chim, and complete the following self-assessment questions.
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Questions 1-10: Please answer T (true) or F (false) 
1. MDS is characterised by peripheral cytopenia with a hypercellular bone marrow
2. There are 5 disorders under the FAB classification
3. The risk of lung cancer is increased in patients with MDS
4. The risk of leukaemia is NOT increased in MDS
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Introduction
Fungal infections in neutropenic patients have always
posed a great challenge even to the most experienced
clinician. Patients are immunocompromised in dismal
situations with high mortality (invasive aspergillosis 58-
87%, systemic candidiasis 40-60%)1, and only prompt
diagnosis with effective antifungal treatment will
salvage these patients. Despite advances in methods of
early diagnosis of invasive aspergillosis, such as serial
measurement of peripheral blood galactomannan
antigen or circulating Aspergillus DNA2, clinical
presentations are often late and diagnosis is delayed.
With the introduction of the new echinocandins class of
antifungal agent and the new triazoles including
voriconazole and posaconazole, successful treatment is
more likely with less toxic effects. In this article, we will
discuss the different classes of antifungal agents and
their applications in different clinical scenarios.
Antifungal Agents
Triazoles
The triazole antifungals target the fungal cytochrome P-
450 dependent 14 -sterol demethylase3-5. This enzyme
converts the lanosterol to ergosterol, a vital component
of the cellular membrane of fungi. As a result,
ergosterol synthesis is disrupted leading to increased
cell membrane permeability, cell lysis and death. The
triazoles are fungistatic against Candida species and
only voriconazole possesses fungicidal activity against
Aspergillus species6. The triazoles include fluconazole,
itraconazole, voriconazole and posaconazole. Triazoles
are associated with abnormal hepatic function, ranging
from asymptomatic mild liver function derangement to
fulminant hepatic failure. Regular monitoring of the
liver function during antifungal treatment with the
triazoles is recommended.
Fluconazole
Fluconazole is very hydrophilic with an excellent
bioavailability of around 90%. It is available in both oral
and intravenous preparations. Once it is absorbed in the
stomach, it is widely distributed in body fluids and
tissues. It also penetrates well into the cerebral spinal
fluid (CSF), achieving about 80% of the serum level7. It
has potent activity against most of the Candida species;
apart from C glabrata that demonstrates significant
resistance to fluconazole. It has no activity to C
norvogenesis, C ciferrii and C krusei. It is active against
Cryptococcus neoformans, Trichosporon, histoplasmosis
and coccidioidomycosis. It has no activity against
Aspergillus, Fusarium and other moulds.
Itraconazole
Comparing to fluconazole, the bioavailability of
itraconazole is much reduced. It varies with different
formulations, ranging from 30% in the solution
formulation to 55% in the capsule formulation. It also
requires an acidic environment for solubilisation in the
capsule form and absorption is increased with food and
acidic drinks8. Proton pump inhibitors that reduce the
gastric pH should be avoided. It is lipophilic and cannot
penetrate the blood brain barrier. In addition to the
Candida species, itraconazole is a second-line agent for
the treatment of aspergillosis.
Voriconazole
It is available in both the oral and intravenous
formulations. Similar to fluconazole, it has an excellent
bioavailability of over 90%. It is widely distributed in
body fluid and tissues including the CSF. It is
metabolised by the cytochrome P450 enzyme9. It is
active against the C glabrata, C norvogenesis, C ciferrii and
C krusei that fluconazole has no action against. It
possesses an enhanced activity against Aspergillus and
Fusarium species.
Posaconazole
Currently, it is only available in the oral formulation.
Similar to fluconazole and voriconazole, it has an
excellent bioavailability. It undergoes hepatic
metabolism and is eliminated in the faeces10. In addition
to its activity against Aspergillus and Fusarium, it is also
active against the Zygomycetes.
Polyenes
The polyenes interact with fungi membrane ergosterols
to produce an aggregate that forms a transmembrane
channel, allowing the cytoplasmic contents to leak out
and subsequent fungal cell death11.
Amphotericin B
This is a polyene originally extracted from Streptomyces
nodosus. It is insoluble in water and all preparation of
amphotericin B must be infused in 5% dextrose. It is
fungicidal against all Candida and Aspergillus species,
Coccidioides immitis, Histoplasma capsulatum, Blastomyces
dermatitidis, Cryptococcus neoformans and Sporothrix
schenckii. It has no activity against Fusarium and
Trichosporon12. Synergistic activity of amphotericin B
with flucytosine has been demonstrated against
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serious Cryptococcal infection, especially in
immunocompromised patients. Nevertheless, serum
flucytosine level should be monitored if patients
develop amphotericin B related nephrotoxicity.
As previously mentioned, the main side effect of
amphotericin B is nephrotoxicity that manifests
initially by kaliuresis and hypokalaemia, then fall in
serum bicarbonate. Renal injury can be reduced by
pre infusion hydration with 500ml saline and
avoidance of other nephrotoxins. Infusion related
adverse reactions like fever, chills and headache could
be minimised by premedication with anti-histamine,
corticosteroid or paracetamol. Prolonging the infusion
time to 12 hours or continuous intravenous infusion
over 24 hours may prevent these reactions13.
Liposomal Amphotericin B
Liposomal formulation of amphotericin B reduces its
nephrotoxicity side effect and improves its tolerance,
without reducing its efficacy. Nevertheless, use of
liposomal amphotericin B is hindered by its cost.
Echinocandin
Echinocandin inhibits synthesis of -(1,3)-D-glucan, a
critical component of fungal cell walls via
noncompetitive inhibition of the enzyme 1,3-　
synthetase14,15. It is fungicidal against most Candida
species and fungistatic against Aspergillus species, with
minimal activity against the dimorphic fungi. It also
demonstrates modest activity against the spore form of
Pneumocystis carinii. It is not active against Fusarium
and Rhizopus. The echinocandins are embryotoxic
(category C) and should not be used in pregnancy.
Patients with chronic liver disease need dosage
adjustment. Other minor side effects include nausea,
vomiting, diarrhoea, headache and hypersensitivity
related rash and pruritis.
Caspofungin
The first approved echinocandins. It has low oral
bioavailability and thus must be given intravenously
only. The drug is well tolerated and non-nephrotoxic.
It interacts with cyclosporine, causing deranged
hepatic parenchymal enzyme. Concomitant use of the
two drugs is not recommended. Dosage reduction in
patients with moderately deranged liver function is
recommended.
Micafungin
Another echinocandin, indicated for the treatment of
candidaemia, disseminated candidiasis and Candida
peritonitis. It was recently approved for the
prophylaxis of Candida infections in patients
undergoing haematopoietic stem cell transplantation.
Anidulafungin
The third echinocandin, indicated for invasive Candida
and Aspergillus infection. It differs from other
echinocandins in that it undergoes chemical
degradation to inactive forms at body pH and
temperature. It does not rely on hepatic or renal
excretion and thus does not require dosage reduction.
Clinical Scenario Requiring Systemic
Antifungal Agents
Empirical Treatment for Neutropenic Fever
Neutropenic fever in a patient is defined as a sustained
temperature of >38oC for more than one hour with an
absolute neutrophil count (ANC) < 500 cells/mL16.
Threshold for initiation of empirical antifungal
treatment for neutropenic fever varies from centre to
centre. In general, if fever persists after five days of
antibiotics therapy and no microbiological pathogen is
isolated, previous guidelines recommended to add
amphotericin B to the antibiotics that the patient is
already receiving16. Recent trials however have
demonstrated that caspofungin was associated with a
significantly higher survival rate at seven days after
the completion of therapy and a superior safety profile
than amphotericin B17. The primary choice is
caspofungin as first-line empirical therapy in patients
with suspected fungal infections. Voriconazole and
liposomal amphotericin B are effective alternates18. It is
important to bear in mind that echinocandins are
inactive to Fusarium and Cryptococcus neoformans that
were previously mentioned. Besides antifungal
treatment, all catheter in-situ should be replaced19.
Invasive Aspergillosis
The diagnosis of invasive aspergillosis is based on
culture and histology, aided by new tests includes
galactomannan20 and PCR testing21. The Infectious
Diseases Society of America (IDSA) has recommended
voriconazole as the initial treatment of choice for
invasive aspergillosis22. Trials have shown that
voriconazole is superior to standard amphotericin B in
the treatment of invasive aspergillosis in terms of both
partial and complete response, lower mortality rate,
better tolerance and severe adverse reactions23. Similar
efficacy and safety profile is expected from
posaconazole24. Itraconazole is considered a second-
line treatment when compared to voriconazole, based
on its inferior intrinsic activity against aspergillosis.
Echinocandins are also active against invasive
aspergillosis with a good tolerance25. However, due to
the lack of data on echinocandins for the treatment of
invasive aspergillosis, voriconazole is the treatment of
choice. Antifungal combination has great potential to
improve outcome based on observational study. In
vitro results have shown additive effect with
combination therapy with caspofungin and
voriconazole26, whereas combinations of caspofungin
and amphotericin B have a synergistic effect27. Most of
the in vivo data showed that the use of voriconazole
and caspofungin combination therapy for the
treatment of invasive aspergillosis showed improved
clinical outcomes and reduced mortality. Combination
therapy with caspofungin and amphotericin B showed
similar results. However, combination therapy with
the azoles and amphotericin B is not recommended
based on the fact that azole inhibits the ergosterol
biosynthetic pathway thereby reducing the
amphotericin B binding to the fungal membrane28.
Nevertheless, spontaneous recovery of bone marrow
function with or without the assistance of granulocyte
colony-stimulating factor (G-CSF) is the utmost
important factor to recovery of invasive aspergillosis.
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Candidaemia
Candidaemia is defined as the presence of Candida
species in blood. Patients are at risk of developing
candidaemia if they are immunocompromised or under
intensive care, especially if they have a central venous
catheters in-situ, on broad-spectrum antibiotics and on
haemodialysis. Diagnosis of candidaemia is based on
blood culture with the BACTEC system29. Other
methods of diagnosis include tissue biopsy and antigen
testing with beta-D-glucan assay30. All intravenous
catheters should be removed and replaced.
Amphotericin B deoxycholate was previously the
antifungal of choice, with rapid fungicidal action against
the Candida species. Unfortunately, its usage is limited
by its nephrotoxicity. The less toxic lipid formulation of
amphotericin B however, is much more expensive. The
azoles are still active against the C albicans. However, C
krusei is intrinsically resistant to fluconazole due to an
altered cytochrome P-450 isoenzyme31 but remains
susceptible to voriconazole and posaconazole. C glabrata
isolates are resistant to the azoles secondary to drug
efflux and cross-resistance among the azoles is
common32. Echinocandins however, remains a potent
antifungal against most Candida species including C
krusei and C glabrata with an excellent safety profile.
Trials have compared caspofungin against amphotericin
B33 and micafungin against liposomal amphotericin B34
for the treatment of invasive candidasis. All trials
showed similar efficacy between the two antifungals but
the echinocandins are associated with less drug toxicity.
In general, echinocandins are the drug of choice for
unstable neutropenic patients who have evidence of
invasive Candida infection, previously exposed to
fluconazole and in institutions where C glabrata or C
krusei is a common isolate. Echinocandins are superior to
amphotericin B in terms of safety profile and cost
effectiveness when compared to liposomal amphotericin
B. Voriconazole and liposomal amphotericin B are
second choice. However, cross-resistance with
fluconazole may affect voriconazole efficacy35.
Hepatosplenic Candidiasis
This occurs in patients with haematological
malignancies who have recovered from an episode of
neutropenia after chemotherapy. Discrete
microabscesses of Candida are found in the liver, spleen
and kidneys. The 2004 IDSA guidelines suggested that
fluconazole is the first line drug of choice36.
Amphotericin B or liposomal amphotericin B may also
be used as initial therapy for the first two weeks, follow
by long-term therapy with oral fluconazole.
Caspofungin is another choice.
Zygomycosis (Mucormycosis)
Combination of surgical debridement and antifungal
therapy with lipid formulation of amphotericin B37 or
posaconazole38 is the treatment of choice for
zygomycosis. Underlying diseases including
hyperglycemias, metabolic acidosis and deferoxamine
administration should also be treated.
Fursarium Infection
This filamentous fungus has become an important
infection in the immunocompromised. Amphotericin B
is the most commonly used antifungal for Fusarium39.
With the emergence of voriconazole40 that is fungicidal
against filamentous fungi with much fewer adverse
effects, it is an alternate to amphotericin B. Posaconazole39
is also active against Fusarium. In view of the high
mortality with disseminated Fusarium infection, a
combination therapy of voriconazole and lipid
formulation of amphotericin B is a good salvage therapy.
Conclusions
For immunocompromised patients, treatment with
antifungal agents not only suppresses the fungal growth
but also buys time to allow patients to recover from
neutropenia. Clinical suspicion, prompt diagnosis and
early treatment are the keys to success in eradication of
fungal infection. Supportive therapy with G-CSF may
hasten neutrophil recovery and functions. New
antifungal agents including echinocandins and the new
triazoles will overcome resistant strains with greater
efficacy and less toxicity.
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Introduction
Lung cancer has been a major health problem
worldwide, accounting for a global incidence of 1.2
million new cases yearly and a staggering mortality of
1.1 million deaths in 2001.1 In Hong Kong, lung cancer
has remained the commonest malignancy in men and
the third commonest in women, with a total of 4,135
new cases in 2005. Being the commonest cancer killer in
both sexes, there were 3,686 deaths in the same year
(Hong Kong Cancer Registry). The majority (>80%) of
lung cancers are non-small cell carcinomas (NSCLC),
which are predominantly in advanced or metastatic
stages upon presentation. The high mortality is mainly
ascribed to disease recurrence after curative lung
resection and the lack of effective treatment for
advanced disease. The overall treatment plan for
NSCLC largely depends on clinical staging: curative
lung resection for early stages (mainly stage I and II),
combined chemoradiotherapy for locally advanced
stages (mainly stage III), and systemic platinum-based
chemotherapy for advanced metastatic stages (mainly
stage IIIB and IV). Prior to our understanding of
molecular tumour biology of NSCLC, the use of
systemic chemotherapy has been targeting at rapidly
growing tumour cells in a rather non-specific fashion. In
principle, a more specific approach that works on
salient molecular pathways for tumourigenesis, i.e.
targeted therapy, may help to enhance clinical efficacy
while minimising toxicities related to damage of normal
tissues. This review serves to summarise the current
state-of-the-art targeted approach in the treatment of
NSCLC.
Anti-angiogenesis
The majority of patients with NSCLC presented with
unresectable diseases, due to regional involvement of
mediastinal lymph nodes, pleural or pericardial
malignant effusion, or distant metastases. In the past
decade, systemic chemotherapy has become the
standard first-line treatment for those with malignant
effusion or distant metastases.2 In such patients with
good performance status, a combination of platinum
(cisplatin or carboplatin) and a newer generation
chemotherapeutic agent (e.g. paclitaxel, docetaxel or
gemcitabine) has been well-documented to improve
overall survival, disease-free survival and quality of life
compared to best supportive care alone or older
generation chemotherapy combinations.3 However, the
improvement in survival is considered modest (on
average 2 months prolongation of median survival
compared to best supportive care alone) and the time
to disease progression is usually within a few months
since commencement of chemotherapy.4
In general, malignant tumours cannot grow beyond
2mm in size without developing a vascular supply.5
The process of neovascularisation also provides a
channel for tumour cells to migrate to the systemic
circulation and subsequent development of distant
metastases. In fact, tumours remain dormant and
unable to metastasise in the absence of a functional
vascular supply . 6,7 Angiogenesis , whether
physiological or pathological, is controlled by the
balance between proangiogenic and antiangiogenic
factors8 (Table 1). The most important proangiogenic
factor involved in tumour angiogenesis is vascular
endothelial growth factor (VEGF), which has become
the target for antiangiogenic therapy in NSCLC.9 The
VEGF pathway can be inhibited by agents that target
VEGF or VEGF receptors. In particular, bevacizumab
(AvastinTM) is an anti-VEGF recombinant humanised
monoclonal antibody, which contains the human
immunoglobulin G1 framework (93%) and murine
VEGF-binding complementarity-determining regions
(7%) blocking the binding of VEGF to its receptors and
subsequent downstream biologic activities. A
randomised phase II study of bevacizumab in
combination with carboplatin and paclitaxel or same
chemotherapy alone as first-line treatment in patients
with stage IIIB or IV NSCLC has demonstrated
superior response rate, time to progression and
survival in the bevacizumab combination arm, with
increased risk of life-threatening haemoptysis in
squamous cell carcinoma.10
In view of these promising results, a recent randomised
phase III study (E4599) was conducted comparing the
combination of bevacizumab with chemotherapy
(carboplatin and paclitaxel) versus chemotherapy alone
in the treatment of advanced chemonaive non-
squamous NSCLC.11 There was a statistically
significant survival advantage that favoured the
bevacizumab combination arm (median survival 12.3
months vs 10.3 months in bevacizumab vs
chemotherapy alone arms, hazard ratio for death 0.79,
p=0.003). The major reported toxicities in bevacizumab
versus chemotherapy alone arms were grade 3/4
neutropenia (25.5% vs 16.8%), grade 3/4 hypertension
(7% vs 0.7%), grade 3/4 proteinuria (3.1% vs 0%) and
grade 3/4 haemorrhage (4.4% vs 0.7%). Out of the 17
treatment-related deaths, 15 were in bevacizumab arm
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and 2 in chemotherapy alone arm, in which the 5 deaths
related to haemoptysis were exclusively from the
bevacizumab arm. This is the first landmark study to
demonstrate superiority in combination of targeted
therapy and chemotherapy compared to chemotherapy
alone (standard-of-care) in the first-line treatment of
patients with advanced NSCLC. In addition, another
similar study has been conducted with the combination
of bevacizumab and gemcitabine and cisplatin in
advanced NSCLC (AVAiL study), with interim results
suggesting favourable progression-free survival in the
bevacizumab arm compared to chemotherapy alone arm.
Epidermal Growth Factor Receptor
(EGFR) Inhibition
Upon disease progression after first-line chemotherapy
treatment, docetaxel as monotherapy has been shown
to be superior to best supportive care alone or
alternative chemotherapy in survival.12,13 The newer
chemotherapeutic agent, pemetrexed, has also been
shown to have similar efficacy as docetaxel with lesser
degree of adverse effects especially myelosuppression
in the second-line setting.14 However, this is still
limited by the very modest improvement in median
survival and also the toxicity profile in the second-line
setting especially for those patients with poor
performance status.
With advancement in molecular research, it becomes
logical to target specific and crucial pathways involved
in carcinogenesis to achieve better control of tumour
growth while minimising the detrimental effects on
normal body tissues. This concept of molecularly
targeted therapy has been best exemplified by the
inhibition of EGFR pathway in the treatment of
NSCLC. The EGFR forms part of the signalling
pathway that regulates tumour cell proliferation,
invasion, angiogenesis, metastasis, and apoptosis.
Since overexpression of EGFR is commonly found in
NSCLC, various novel agents that inhibit EGFR
pathway have been developed for treatment of this
neoplasm. Apart from the use of monoclonal antibody
that targets the EGFR extracellular binding site, small
molecules that target the intracellular adenosine
triphosphate (ATP) binding site of EGFR tyrosine
kinase have been studied extensively.
Gefitinib (IressaTM) was the first EGFR tyrosine kinase
inhibitor (TKI) used in the treatment of advanced
NSCLC. Previous large-scale phase III trials (INTACT 1
and 2) failed to show clinical benefit by combining
gefitinib with platinum-based chemotherapy in first-
line treatment of advanced NSCLC.15, 16 It was based on
two large phase II trials (IDEAL 1 and 2) of gefitinib
monotherapy in previously treated patients with
advanced NSCLC that was approved as second-line
treatment.17, 18 From these trials, the objective response
rate was up to 18% with encouraging median survival
of 7-8 months, without the inclusion of a placebo arm.
The most common toxicities were skin rash and
diarrhoea, with rare occurrence of interstitial
pneumonitis. Later a randomised, placebo-controlled,
phase III study (ISEL) was reported on gefitinib versus
placebo in treatment of advanced NSCLC patients who
were refractory or intolerant to chemotherapy.19 It was
shown that gefitinib (250mg daily) was not associated
with significant improvement in survival compared to
placebo (median survival 5.6 vs 5.1 months in gefitinib
vs placebo), despite some benefit among never smokers
and patients of Asian descent. The commonest toxicities
were skin rash (37%) and diarrhoea (27%). On the other
hand, the preliminary results of a more recent phase III
study of gefitinib versus docetaxel as second-line
treatment for advanced NSCLC (INTEREST trial)
suggested similar clinical efficacy between gefitinib and
docetaxel.
Erlotinib (TarcevaTM) is a later developed EGFR TKI that
has also been extensively studied in treatment of
NSCLC. Similar to gefitinib, large-scale phase III trials
(TALENT and TRIBUTE) showed no clinical benefit in
adding erlotinib to standard platinum-based
chemotherapy as first-line treatment of advanced
NSCLC.20 A recent randomised, placebo-controlled,
phase III trial of erlotinib versus placebo in treatment of
advanced NSCLC after failure to previous
chemotherapy was reported.21 The erlotinib treatment
arm was found to be superior in response rate (8.9% vs
1%), progression-free survival (2.2 vs 1.8 months) and
overall survival (6.7 vs 4.7 months) compared to
placebo arm. The more frequent adverse effects
associated with erlotinib treatment were skin rash (76%
vs 17%), anorexia (69% vs 56%), stomatitis (19% vs 3%),
diarrhoea (55% vs 19%), ocular toxic effect (28% vs 9%)
and infection (34% vs 21%) compared to placebo.
From the studies of gefitinib and erlotinib in treatment
of advanced NSCLC, several clinical and molecular
predicting factors for response to treatment were
identified.22 (Table 2) Specific mutations in the EGFR
tyrosine kinase domain (exons 18-21) have been shown
to be associated with treatment response, while other
mutations might predict drug resistance. Therefore this
class of novel agents is particularly effective in NSCLC
patients with favourable characteristics (female, Asian
descent, never smokers, adenocarcinoma, specific EGFR
mutations), which often serve as the selection criteria
for treatment. However, there are still controversies
about the best molecular markers (either single or
multiple) for response and survival outcome, and there
is still lack of good predictors of the group with disease
stabilisation after treatment.
Future Directions of Targeted Therapy
in NSCLC
Targeting specific molecular signalling pathways
remains a promising approach in the management of
NSCLC. However there are still several issues that need
to be addressed. First, there is a clear need of better
characterisation of "targeted" patient subpopulation that
may potentially benefit from a particular targeted
approach. Future research in identifying biomarkers that
reliably predict clinical treatment outcomes is warranted.
Second, the potential use of EGFR TKI in clinical settings
other than second or third-line in advanced NSCLC
needs to better defined, especially in the adjuvant
treatment for early-stage disease after curative lung
resection or the first-line treatment for advanced disease.
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Third, the problem of acquired resistance to EGFR TKI
(mostly related to a new mutation in EGFR) requires
further research. In fact, there have been some newer
generations of EGFR TKI that are currently under
investigations for overcoming drug resistance to
gefitinib or erlotinib. Last, as there has been better
understanding about the potential interactions or cross-
talks between different signalling pathways, it becomes
logical to simultaneously target different molecular
pathways in order to achieve better tumour control. As
a result, there have been quite a number of multi-
targeted tyrosine kinase inhibitors (e.g. inhibiting both
VEGF and EGFR) that are currently undergoing clinical
trials in the treatment of NSCLC.
Conclusion
Although lung cancer, predominantly NSCLC, is still
considered to be a devastating malignancy with 5-year
survival less than 15%, there has been major
advancement in the overall treatment especially in the
era of targeted therapy. With our continuing efforts in
research along the targeted approach, lung cancer will
hopefully become a chronic condition like hypertension
or diabetes in the near future.
Table 1 Common endogenous proangiogenic and antiangiogenic
factors*
Proangiogenic factors
Acidic and basic fibroblast growth
factor
Angiogenin
Hepatocyte growth factor
Interleukin-8
Placenta growth factor
Platelet-derived endothelial cell growth
factor
Transforming growth factor- -
Tumour necrosis factor-
Vascular endothelial growth factor
Antiangiogenic factors
Angiostatin
Endostatin
Interferon- -
Interferon inducible protein-10
Platelet factor 4
Prolactin fragment
Thrombospondin
Tissue inhibitor of metalloproteinase
Tumstatin
Vasculostatin
Table 2 Predictors for response to EGFR TKI in patients with
advanced NSCLC*
Clinical
East Asian descent
Female gender
Nonsmokers
Adenocarcinoma histology
Skin rash
Molecular
EGFR TK domain-sensitizing mutations
EGFR polymorphisms
EGFR amplification
ErbB3 expression
* Adapted from reference no. 8
* Adapted from reference no. 22
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Introduction
Breast cancer is the most common female cancer in the
world.1 It is also the most common female cancer in
Hong Kong with 1 in 22 cumulative life-time risk.2
Over the last two decades, there have been remarkable
advances in the screening, diagnosis and treatment of
breast cancer. Surgical resection of the primary tumour
remains the basis for cure of early breast cancer.
Adjuvant radiotherapy is given according to the
tumour risk to help prevent local recurrence. Adjuvant
chemotherapy and/or endocrine therapy help to
prevent disease relapse by targeting occult
micrometastasis. Through understanding new
pathways, pharmacogenomics and predictors of
response, the outcome of breast cancer has improved
dramatically in recent years with the advent of targeted
therapy while the choice of therapy depends not only
on risk assessment incorporating both patient and
tumour-related prognostic factors, but also biomarkers
and drug toxicity profile.
Adjuvant therapy has proven to be effective in
preventing both local and distant relapses.3
Traditionally, the selection of adjuvant systemic
therapy has relied on both patient and tumour-related
factors. Patient factors include age at presentation,
menopausal status and comorbidities. Tumour-related
factors include tumour size, tumour grade, lymph
node involvement, the presence or absence of
oestrogen receptors (ER), progesterone receptors (PgR)
and the HER-2 receptor status.
Evolution of Chemotherapy for
Breast Cancer
Indications for Adjuvant Chemotherapy
Randomised trials have shown improved survival
with the use of adjuvant chemotherapy after breast
cancer surgery.3 Young age at presentation,
pathological tumour size of more than 2 cm, high
grade of tumour, presence of peritumoural vascular
invasion, positive axillary lymph nodes, hormone-
negative tumours and over-expression or amplification
of the HER2/neu gene are indications for adjuvant
chemotherapy.4 However, adjuvant treatment should
be tailored to individuals, taking into account patients'
comorbidities and preferences.
Adjuvant Chemotherapy - Past and Present
In the 1970s, CMF (Cyclphosphamide, Methotrexate
and 5-FU) was the backbone of adjuvant
chemotherapy for breast cancer.3,5 The Milan research
group decided in the early 1980s to challenge CMF by
introducing anthracycline-based regimens in the
adjuvant setting. Compared with standard CMF,
anthracyclin-containing regimens reduced the annual
risk of recurrence by 12% and the annual risk of death
by 11%.3 This difference was seen with regimens such
as FAC (5-FU, Adriamycin, Cyclophosphamide) and
FEC (5-FU, Epirubicin, Cyclophosphamide), whereas 4
cycles of AC (Adriamycin, Cyclophosphamide)
appears to be equivalent to 6 cycles of CMF and has
become a standard adjuvant regimen.6,7 The taxanes
were introduced into clinical practice in the 1990s, and
have emerged as powerful compounds in breast cancer
in several adjuvant clinical trials. The addition of four
cycles of paclitaxel (Taxol®) after a standard course of
AC was shown to improve the disease-free survival
(DFS) and overall survival (OS) of patients with node-
positive primary breast cancer.8 The Breast Cancer
International Research Group (BCIRG) 001 study
showed similar enhancement of DFS and OS with the
use of adjuvant docetaxel (Taxotere®). Significant
improvement of DFS was seen in 6 cycles of TAC
(Docetaxel , Adriamycin, Cyclophosphamide)
compared to 6 cycles of FAC (82% vs 74%).9 In a
recent randomised phase III study, 4 cycles of TC
(Docetaxel, Cyclophosphamide) were shown to be
superior to AC, in terms of improved DFS. TC is
associated with more peripheral neuropathy, myalgia
and arthralgia and febrile neutropenia while AC is
associated with more nausea and vomiting and
cardiotoxicity. Currently, TC is considered as an
alternative to AC especially in patients with
background of significant heart disease.10
Discovering the Optimal Dose and Schedule
Duration and the most optimal schedule of adjuvant
chemotherapy are also being critically reappraised.
Recent study has shown that treatment with AC
followed by weekly paclitaxel is associated with
improved DFS and OS in comparison with treatment
with AC followed by 3-weekly paclitaxel regardless of
hormone receptor expression.11 On the other hand,
dose-dense regimens, i.e. giving the same type of
chemotherapy with same dosage every 2 weeks
instead of every 3 weeks with continuous recombinant
granulocyte colony-stimulating factor (G-CSF)
support, have been shown to improve both the DFS and
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OS with lower incidence of febrile neutropenia in the
dose-dense group.12
HER-2 Targeted Therapy 
Targeting HER-2 with Trastuzumab
Up to 25% of women with breast cancer have human-
epidermal growth factor receptor 2 (cerbB-2 / HER-2)
positive disease, which is associated with aggressive
disease, a higher risk of relapse and a poorer
prognosis.13,14 Trastuzumab (Herceptin®), a monoclonal
antibody directed against the extracellular domain of
HER-2, improves survival and quality of life when
given in combination with taxanes as first-line therapy
in women with metastatic breast cancer.15, 16 It could be
either given as monotherapy or as a chemosensitiser in
combination with cytotoxics such as taxanes or
vinorelbine, and has demonstrated activity in heavily
pretreated patients17. Four major international adjuvant
trials - Herceptin® Adjuvant (HERA), National Surgical
Adjuvant Breast and Bowel Project (NSABP) B-31,
North Central Cancer Treatment Group (NCCTG)
N9831, and Breast Cancer International Research Group
(BCIRG) 006 - including >13, 000 women with HER-2
positive breast cancer, have shown that one-year
treatment of trastuzumab after adjuvant chemotherapy
significantly improves DFS and OS among women with
HER-2 positive breast cancer.18 A small Finnish trial,
FinHer, investigating another regimen of trastuzumab,
has also shown similarly positive results.19 Meta-
analysis of these five randomised trials further
supported the above benefits in terms of disease-free
and overall survival.18, 20
Trastuzumab is not associated with the adverse events
that occur typically with chemotherapy such as
alopecia, myelosuppression or vomiting. It is generally
well tolerated, but occasionally associated with
hypersensitivity or acute reaction which is seen mainly
with the first infusion. Cardiotoxicity such as congestive
heart failure remained at an acceptable level with
reported overall incidence of about 0.6-4.1%.19 This is
usually reversible when the drug is suspended.
Therefore, close monitoring of the cardiac function with
baseline and 3-monthly echocardiogram or MUGA scan
is recommended.
Lapatinib - A Dual Tyrosine Kinase Inhibitor
Another novel targeted therapy, Lapatinib, is an oral
dual small molecule tyrosine kinase inhibitor targeting
both ErbB-2 (HER-2 / neu) and ErbB-1 (EGFR)
receptors. It is active in combination with capecitabine
(Xeloda®) in women with HER2-positive metastatic
breast cancer that has progressed after anthracycline,
taxanes and trastuzumab-based therapy, leading to
significantly longer median time to progression and
progression-free survival.21 Lapatinib is active in
refractory metastatic breast cancer with potential
benefit in patients with brain metastases. It has very low 
incidence of cardiotoxicity and is well tolerated.22
Results from the phase III randomised, double-blind,
multicentre, placebo-controlled trials of lapatinib in the
adjuvant setting such as the TEACH (Tykerb®
Evaluation After Chemotherapy) trial are eagerly
awaited to determine the role of lapatinib in the
adjuvant setting.
Adjuvant Hormonal Therapy with
Aromatase Inhibitors
The Advent of Aromatase Inhibitors
About two-thirds of women with breast cancer have
positive oestrogen receptors and/or progesterone
receptors and are candidates for adjuvant endocrine
therapy. Five years of Tamoxifen, the selective
oestrogen receptor modulator, has been the standard
adjuvant hormonal therapy for women with hormone-
positive disease since the 1970s.23 Aromatase inhibitors
are inhibitors of oestrogen biosynthesis, blocking
aromatase, the enzyme responsible for converting
androgens to oestrogens, thus suppressing oestrogen
levels with no partial agonist activity. The third-
generation aromatase inhibitors (AIs) which were
introduced in the late 1990s, have expanded the
adjuvant endocrine treatment options for
postmenopausal women with hormone-receptor
positive breast cancer and were shown to be superior to
tamoxifen in improving the disease-free survival in
several large, randomised controlled clinical trials.23 The
currently available AIs include the nonsteroidal
compounds anastrozole (Arimidex®) and letrozole
(Femara®), and the steroidal AI exemestane
(Aromasin®).
Tamoxifen Remains the Gold-standard for Pre-
menopausal Women
To date, tamoxifen remains the gold-standard for
hormone-receptor positive disease in pre-menopausal
women. Other options of ovarian function suppression
include ovarian ablation by surgery or radiation, and
the use of gonadotropin-releasing hormone (GnRH)
agonists in the case of persistent ovarian activity after
chemotherapy. Aromatase inhibitors are inactive in pre-
menopausal patients and should not be used because in
these women, AIs induce an increase in gonadotropin
secretion secondary to the reduced negative feedback of
oestrogen to the pituitary, leading to ovarian
stimulation and a potential increase in ovarian size and
function.1
Different Adjuvant Strategies with Aromatase
Inhibitors
Recent large, randomised controlled clinical trials have
shown consistently the superiority of AIs over
tamoxifen in postmenopausal women with early breast
cancer and AIs are recommended to form part of the
adjuvant endocrine therapy.1 Three different strategies
for integrating the use of AIs with tamoxifen as
adjuvant therapy for hormone-responsive breast cancer
include: (1) upfront 5-year use of an AI as an alternative
to tamoxifen in the initial adjuvant setting ("primary
upfront approach")24,25; (2) "switching approach"
whereby giving the patient 2-3 years of AI instead of
tamoxifen after the patient survives disease free for 2-3
years of tamoxifen ("unplanned switching strategy") or
planned from the time of surgery ("planned sequence
strategy")25-28; and (3) as an extended adjuvant therapy,
whereby the patient receives further 5-year AI therapy
following completion of the recommended 5-year
course of tamoxifen.29, 30
However, it is unclear whether one of these AI
strategies is superior to the other ones. The overall
therapeutic index of AIs appears superior to that of
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tamoxifen with proven improved efficacy and a better
toxicity profile. AIs are less toxic than tamoxifen in
terms of thromboembolic disease and endometrial
carcinoma, while myalgia, arthralgia, increased
tendency of osteoporosis and bone fracture are more
frequently observed with AIs.
Bisphosphonates: Benefits Beyond Bones
Breast cancer patients with bony metastases experience
fewer skeletal-related events31 and require less radiation
therapy.32 The use of adjunct bisphosphonate therapy
with adjuvant aromatase inhibitors has been proven to
reduce treatment-related osteoporosis.33 In the recent
American Society of Clinical Oncology (ASCO) 2008
annual meeting, it was reported that the addition of
zoledronic acid every 6 months to adjuvant endocrine
therapy with tamoxifen or aromatase inhibitors have led
to significantly prolonged DFS and OS in breast cancer
women compared endocrine treatment alone group. This
large clinical trial has demonstrated that anti-tumour
activity of adjuvant bisphosphonate improves outcome
beyond the effect of endocrine therapy alone.34
Tailoring Treatment for Individuals
With understanding of the biology of breast cancer in
the era of targeted therapy and tailored management of
cancer patients, the hormone receptors and the HER-2
receptor remain the two main targets in breast cancer
management. The selection of the most optimal
management plan depends not only on the patient and
tumour-related factors, but also the stage of the disease,
and the predicted responsiveness of the tumour by
molecular profiling while respecting patient's wish.
Neoadjuvant Systemic Therapy
Neoadjvuant, or pre-operative systemic therapy is
increasingly used for patients with clinical stages II and
III breast cancer to improve surgical outcomes. This
application is not confined to inoperable or locally
advanced breast cancer, but in the setting of operable
disease with more aggressive curative intent and the
aim of downstaging and downsizing the tumour,
increasing the chance of breast-conserving surgery and
assessing the drug sensitivity and treatment response.
Patients who achieved a complete pathological response
after neoadjvuant chemotherapy have demonstrated
significantly superior DFS and OS compared to those
who did not. Updated results also showed trends in
favour of neoadjuvant chemotherapy for DFS and OS in
women younger than 50 year-old.35 Postmenopausal
women with clinical stages II and III oestrogen
receptor-positive breast cancer who are downstaged to
pathological stage I disease with neoadjuvant endocrine
therapy such as aromatase inhibitors have
demonstrated favourable long-term outcome.
Improving Tolerability of Palliative Treatment
and Directing at New Targets
Due to recent multiple advances in the treatment of
breast cancer, more women with early breast cancer have
become cancer survivors, while many women with
aggressive disease or advanced disease at presentation
live with their breast cancer for significant period of time.
Newer anti-cancer drugs have emerged with excellent
potency but minimal toxicity. These include the better
tolerated chemotherapy such as vinorelbine, gemcitabine
and oral fluoropyrimidines (capecitabine) with minimal
hair-thinning and vomiting. On top of targeted therapy
such as trastuzumab and lapatinib, there is another new
wave of monoclonal antibodies and tyrosine kinase
inhibitors emerging. The combination of bevacizumab,
monoclonal antibody against the vascular endothelial
growth factor receptor (VEGF) and taxanes has shown
activity in patients with metastatic breast cancer with
increased progression-free survival.36 Again, selection of
palliative therapy should be based upon both the patient
and tumour characteristics. Elderly patients with multiple
comorbidities who have hormone-positive disease with
bony metastasis only but no visceral disease may do well
with hormonal therapy with AI but not necessarily
chemotherapy, and all these new combinations of
treatment have further improve the quality of life of
breast cancer patients. Another new class of hormonal
agent, Fulvestrant, an oestrogen receptor antagonist has
shown clinical efficacy in postmenopausal breast cancer
women with hormone-positive tumour who progress
after second-line aromatase inhibitors.
Potential Molecular Markers
It is observed that clinical activity of a given drug may
vary between different patients. Different breast cancer
sub-types are now being identified with early preclinical
data suggesting that in the future some molecular markers
might have practical value in predicting treatment
response. Topoisomerase II (TopoII) alpha gene
aberrations are the most promising molecular predictors
of anthrcycline response.37 HER-2/topoII co-amplified
tumours are shown to be most sensitive to anthracyclines.
Triple Negative Breast Cancer
Although there are emerging potential targets for breast
cancer, there is a distinct entity of breast cancer, which
is associated with aggressive behaviour and poor
prognosis, and typically do not express hormone
receptors or HER-2 ("triple-negative" phenotype).
Triple-negative breast cancer with a basal-like
phenotype is characterised by high proliferation rate
and BRCA1 gene dysfunction. Currently patients with
this type of tumour cannot be managed with existing
targeted treatments (trastuzumab and hormonal
therapy) effectively but is associated with better
response with platinum-based chemotherapy.38 Further
study on this particular subtype is recommended.
Conclusion
There is increasing hope for breast cancer patients. The
hormone receptors and HER-2 receptor remain the two
main targets for treatment. Through better
understanding of breast cancer biology, identifying
more new molecular markers and conducting quality
randomised controlled clinical trials, we have achieved
better outcome of breast cancer. At the same time, there
remain many unexplored avenues for optimising the
role of each target and new advances. The era of
personalised medicine will become more complex in the
future and the embracement of multidisciplinary and
evidence-based medicine should continue be the
standard of care for our breast cancer patients.
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Introduction
Worldwide, pancreatic cancer poses a significant health
hazard with more than 200,000 cases diagnosed
annually and the majority of cases are in the developed
countries.1 It is the eighth most common cause of
cancer-related deaths and the number of deaths is
nearly equivalent to the number of newly diagnosed
pancreatic cancer. This reflects the typical dismal
prognosis associated with pancreatic cancer. When the
disease is diagnosed at early stages, the overall 5-year
survival rate is 20 % for patients with localised disease
and 8% for patients with locally advanced disease.2
Unfortunately, most patients with pancreatic cancer
have advanced or metastatic disease upon presentation.
The prognosis of this group of advanced pancreatic
cancer patients is disappointing. In general, the median
survival of untreated advanced pancreatic cancer is
only three to four months. Even in treated patients,
their median overall survival is only approximately 6
months with chemotherapy.
Patients suffered from pancreatic cancer often present
with disease-related symptoms out of proportion to
their tumour burden. The typical symptoms, such as
pain and cachexia severely impact on the quality-of-life
of the patients. Also, due to the poor performance
status of the patients, they are more prone to develop
treatment-related complications, especially after
chemotherapy. It is a challenging disease for the
oncologists to deal with and there is an urgent need to
develop effective systemic therapy to improve the
outcome of the patients.
In recent years, a better understanding of the molecular
signalling pathways in cancer cells has led to the
identification of new therapeutic targets for intervention
and the discovery of promising targeted therapy for the
treatment of otherwise chemo-resistant tumours, such as
renal cell carcinoma.3 Similar to other solid malignancies,
progresses have also been made in the management of
pancreatic cancer patients. This article will concisely
summarise the latest development in the systemic
therapy of pancreatic cancer.
Early Stage Disease And the Role of
Neo-adjuvant And Adjuvant Therapy
Patients with localised pancreatic cancer, usually
involving the head of the pancreas are candidates for
surgery if the tumour is resectable as defined by the
absence of vascular involvement. Notably, complete
surgical resection is the only curative choice. However,
despite recent advances in staging and surgical
techniques, the outcome of patients treated with primary
resection remains poor with a median survival of 13
months and the 5-year survival of 15-20% only.4 As a
result, oncologists are keen to use adjuvant and
neoadjuvant therapy to improve the prognosis of
patients with resectable pancreatic cancer.
The main purpose of the adjuvant therapy is to reduce
the chance of local and distant recurrence in good
performance patients after resection for localised
pancreatic cancer. Previously, post-operative chemo-
irradiation was often employed as two trials from the
Gastrointestinal Tumour Study Group had demonstrated
better survival in using adjuvant chemo-irradiation than
surgery alone in treating resectable pancreatic cancer
patients.5,6 These trials had been criticised for their small
sample size and poor accrual, albeit post-operative
chemo-irradiation was still adopted as the standard
treatment. More recently, a large randomised adjuvant
phase III trial-- European Study Group for Pancreatic
Cancer 1(ESPAC-1) trial conducted mainly in Europe
had challenged the role of adjuvant chemo-irradiation.7,8
In this randomised phase III trial with a 2x2 factorial
design, the data suggested significant survival benefit of
using adjuvant chemotherapy consisted of intravenous
fluorouracil (5-FU) and folinic acid (overall survival of
20.1 versus 15.5 months in the chemotherapy and non-
chemotherapy arm, respectively). Interestingly, patients
who received chemo-irradiation had a detrimental effect
on overall survival (15.9 and 17.9 months in the chemo-
irradiation arm and no chemo-irradiation arm,
respectively). Furthermore, another pivotal phase III
trial-CONKO-0019 demonstrated that patients who had
received gemcitabine as adjuvant therapy had a
significant longer disease-free survival than patients
without adjuvant therapy (13.4 versus 6.9 months,
p<0.001). Moreover, the overall survival also favoured
the use of gemcitabine as adjuvant (22.1 versus 20.2,
p=0.06). However, the US Gastrointestinal Intergroup
trial10 had shown no statistically significant difference in
overall or disease-free survival in patients received
gemcitabine or 5-FU as systemic chemotherapy before
and after 5-FU-based chemo-irradiation as adjuvant
therapy for patients with resectable pancreatic cancer.
However, oncologists nowadays still prefer to use
gemcitabine as adjuvant therapy for patients with
resectable pancreatic cancer due to its easy tolerability.
In the near future, with optimal patient selection,
improved operation techniques and peri-operative care,
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more patients who undergo pancreatic resection will
recover adequately to receive postoperative adjuvant
therapy. Therefore, it is important to develop more
effective adjuvant therapy, especially by incorporation
of biologics to improve the overall survival of resectable
pancreatic cancer.
With respect to the role of neo-adjuvant therapy in
down-staging the advanced pancreatic cancer for
potential curative resection, it is still unclear. Treatment
with 5-FU based chemo-irradiation or gemcitabine only
downstage the disease in a minority of patients with
locally advanced disease. In daily practice, oncologists
tend to treat locally advanced pancreatic cancer patients
with chemo-irradiation with 5/FU as radiosensitiser
followed by palliative chemotherapy. However, two
recent meta-analyses did not show that chemo-
irradiation was better than chemotherapy alone in
patients with locally advanced pancreatic cancer.11,12 In
contrast, the addition of radiotherapy to chemotherapy
increased treatment-related toxicity. Hopefully, all the
on-going neo-adjuvant trials can better define the role
of radiotherapy, chemotherapy and other biologics in
down-staging locally advanced pancreatic cancer.
Management of Metastatic Pancreatic
Cancer
Only a few patients (10-15%) diagnosed to have
pancreatic cancer and have limited stage disease are
amenable to surgical resection. However, even with
surgery, disease recurrence will occur in the majority
of patients despite adjuvant therapy. Therefore,
systemic therapy for patients with advanced
pancreatic cancer is a pressing issue nowadays.
Systemic chemotherapy has its established role in the
management of metastatic pancreatic cancer patients.
It is usually only offered to carefully selected patients
with good performance status. In the treated patients,
they usually have a significantly better median overall
survival with better quality of life as well.13,14
However, despite active treatment, less than 5% of
patients are alive at 5 years.
First-line Treatment of Metastatic
Pancreatic Cancer
In the past, 5-FU was first used as palliative
chemotherapy for patients with metastatic pancreatic
cancer.15 Subsequently, gemcitabine became the
standard of care for advanced pancreatic cancer for the
past decade as in a phase III trial of patients with
advanced pancreatic cancer, gemcitabine was found to
be better than 5-FU in alleviating the symptoms and
associated with a significant longer median survival.16
Therefore, the US Food and Drug Administration (FDA)
approved the use of gemcitabine in the treatment of
advanced pancreatic cancer. The approved schedule of
administration is 1000 mg/m2 over 30 mins once weekly
for up to 7 weeks followed by a week of rest.
Subsequent cycles consist of 30-min intravenous
infusions for 3 consecutive weeks out of 4. Side effects
associated with single agent gemcitabine include
myelosupression, lethargy, an influenza-like syndrome,
nausea and vomiting and peripheral oedema.
Interestingly, the recent clinical trial results suggested
that the efficacy of gemcitabine treatment may be
enhanced by giving gemcitabine as a fixed-dose rate
infusion of 10mg/m2/min, but at the cost of increased
toxicities.17,18 However, it has not yet been shown to
improve overall survival when compared with the
standard administration regimes.19
Although the efficacy of single agent gemcitbine is
superior to bolus 5-FU, its efficacy is modest, with a
median survival of only 6 months in most randomised
trials and a 12-months survival of < 20%. Therefore, in
the past decade, numerous attempts were made to
improve the efficacy of gemcitabine treatment by
adding other chemotherapeutic or biological agents.
Unfortunately, a lot of gemcitabine-based doublets or
triplets have been done with very disappointing
results. Recently, against a background of numerous
negative randomised trials of gemcitabine-based
treatment, two trials have reported significant survival
improvements with the use of combination treatment:
the United Kingdom National Cancer Research
Institute GEMCAP trial and the National Cancer
Institute of Canada Clinical Trials Group PA.3 trial.
The results of the GEMCAP trial are the first in the
literature which show that combination chemotherapy
is better than gemcitabine alone for the treatment of
advanced pancreatic cancer.20 In this randomised
phase III trial, 533 patients were randomised to receive
either single agent gemcitabine (n=266) or gemcitabine
and capecitabine. In patients who received
gemcitabine and capecitabine combination, the median
OS was 7.4 months, compared with 6.0 months for
gemcitabine alone ( hazard ratio 0.8, 95% confidence
interval 0.65-0.98;p=0.026) and absolute 1-year survival
improvement of 7%. The combination regime was
well-tolerated with a similar incidence of grade 3 /4
toxicities in both treatment arms, except more
neutropenia in the combination arm.
On the other hand, the PA.3 trial demonstrated the
survival benefit in combining erlotinib and
gemcitabine for the treatment of advanced pancreatic
cancer patients. Erlotinib is a small-molecule tyrosine
kinase inhibitor (TKI) of the human epidermal growth
factor receptor (EGFR), which has been approved for
the treatment of non-small cell lung cancer.21 EGFR is
dysregulated in many tumour types, including 40-65%
of pancreatic tumours.22 PA.3 was a multi-centre,
randomised, double-blind, placebo-controlled phase
III clinical study of erlotinib in combination with
gemcitabine in patients with advanced pancreatic
cancer. A significant survival improvement in median
PFS was observed in the gemcitabine and erlotinib arm
when compared with gemcitabine single agent (3.8
versus 3.5 months, p=0.006). Moreover, the treatment
was well-tolerated with incidence of adverse events
similar in both arms of PA.3. However, patients who
received erlotinib and gemcitabine complained of
more rashes, diarrhoea, infection and stomatitis.
Although the survival improvement is only modest--
14 days in this study, this is still a significant step
forward in the management of patients with this
notorious malignancy.
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Second-line Therapy
Thus far, there is no standard second-line treatment for
patients with metastatic pancreatic cancer and only 30-
50% of patients will have a chance to receive second-
line treatment. It is mainly attributed to the fact that
many patients who progress with first-line treatment
have suboptimal organ function and poor performance
status. Therefore, they may not be able to tolerate the
second-line chemotherapy well and many clinicians are
quite reluctant to offer systemic chemotherapy in this
setting. Lately, the results of CONKO-3 just released in
the American Society of Clinical Oncology 2008 Annual
meeting.23 In this pivotal phase III trial, patients who
received combination of oxaliplatin plus 5-FU and
leucovorin as second-line regime had significant
improvement in overall survival than patients on 5-FU
and leucovorin alone (26 versus 13 weeks, p=0.014).
Other second-line pancreatic trials using similar
regimes or other combinations are on-going and their
results will better define the role of second-line therapy
in the treatment of gemcitabine-refractory patients.
Role of Biologics in the Management
of Metastatic Pancreatic Cancer
Two pathways play a significant role in pathogenesis of
advanced pancreatic cancer: EGFR and vascular
endothelial growth factors (VEGF).
Blockade of the EGFR pathway with TKI-erlotinib has
demonstrated encouraging results in the PA. 3 trial.
Moreover, another TKI-lapatinib also showed
encouraging activity in combining with gemcitabine-
based treatment in the management of advanced
pancreatic cancer patients.24 However, blocking the
EGFR pathway with monoclonal antibody-cetuximab
instead showed disappointing results. In the US
Southwest Oncology Group study, the addition of
cetuximab to gemcitabine had failed to show survival
benefit than gemcitabine alone.25 It is interesting to note
the phenomenon that there is benefit in using TKI but
not monocloncal antibody in the management of
pancreatic cancer. This phenomenon is in contrast to
our experiences in using this class of drug in the
treatment of other solid tumours. The exact reason is
still not yet known.
Anti-VEGF therapy has shown promising results in the
treatment of other solid tumours. Unfortunately,
targeting VEGF therapy has not yet shown any success
in the management of advanced pancreatic cancer. The
interim results of the US Cancer and Leukemia Group B
failed to show any survival benefits in the addition of
bevacizumab to gemcitabine in the management of
advanced pancreatic cancer patients.26 More mature
data from this and other on-going trials in using
bevacizumab in the management of advanced
pancreatic cancer will better define the benefits of
addition of bevacizumab to gemcitabine-based regime.
Conclusion
Despite recent survival improvement with the addition
of capecitabine and tarceva to gemcitabine-based
treatment of metastatic pancreatic cancer, the benefit is
only modest. Moreover, there is additional cost and
risk of toxicity from combination regime, particularly
the use of erlotinib. Thus, more active and new
systemic regimes are desperately needed to improve the
outcome of patients with advanced pancreatic cancer.
Moreover, further research in the treatment of
pancreatic cancer should be underpinned by an
improved understanding the underlying pathogenesis
of the disease at a cellular, molecular and genetic level.
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(See P. 37 for answers)
Clinical Quiz
Dr. KS Tai
M/44. Presented with low back pain.
MRI scan of the L-S spine was performed.
Please comment on the imaging findings and give
your diagnosis.
Clinical history:
Infective spondylodiscitis of L2-3 with mild
epidural extension.
Osteomyelitis of right ilium.
Diagnosis:
Fig. 1 Fig. 2
Fig. 3 Fig. 4
Consultant, Queen Mary Hospital
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Society News
News from Member Societies:
New Member Society:
British Medical Association (Hong Kong Branch)
Updated office-bearers for the year 2008-2010 are as follows: President: Dr. Adrian WU; Vice-President: Dr.
Raymond LO; Honorary Secretary: Dr. Anthony LI; Honorary Treasurer: Dr. Clarence LEUNG
Hong Kong Association of Sports Medicine & Sports Science
Updated office-bearers for the year 2008-2009 are as follows: President: Dr. Patrick Shu-hang YUNG; Honorary
Secretary: Mr. Raymond Chi-hung SO; Honorary Treasurer: Dr. John Ping-shan WONG
Hong Kong Orthoptists Association
Updated office-bearers for the year 2008-2009 are as follows: Chairlady: Ms. Betty FONG; Vice-Chairman: Mr.
KWOK Shing Chin; Honorary Secretary: Mr. Edmond LEUNG; Honorary Treasurer: Ms. TSANG Chi Shan
The Hong Kong Pain Society Limited
Updated office-bearers for the year 2008-2009 are as follows: President: Dr. CHEN Phoon Ping; Honorary Secretary:
Ms. Rainbow Ka-yee LEUNG; Honorary Treasurer: Dr. Steven Ho-shan WONG
Hong Kong Urological Association
Updated office-bearers for the year 2008-2010 are as follows: President: Dr. Ming-kwong YIU; Honorary Secretary:
Dr. Peggy Sau-kwan CHU; Honorary Treasurer: Dr. Simon Sai-man CHU
The Practising Pharmacists Association of Hong Kong
Updated office-bearers for the year 2008-2009 are as follows: President: Ms. Iris CHANG; Honorary Secretary: Ms.
Rosanna WONG; Honorary Treasurer: Mr. Kevin CHEUNG
Dental Society, HKUSU
Office-bearers: Chairperson: Ms. Carmen Ka-man CHAN; Vice-Chairpersons: Mr. Alvin Yue-hin KUNG, Ms. Roxy
Man-ching NG; General Secretary: Mr. Angus Cheuk-hin HO; Financial Secretary: Mr. Pitar Ho-cheung CHOI
The Hong Kong Society of Cytogenetics Limited
Office-bearers: President: Mr. Wing-kwong CHAN; Honorary Secretary: Dr. Thomas Shek-kong WAN; Honorary
Treasurer: Mr. Kin-wah SUEN
FMSHK would like to welcome The Hong Kong Society of Cytogenetics Limited and Dental Society,
HKUSU as associate member and student member of the Federation respectively.
The Hong Kong Medical Diary Editor's Dinner was held on 27 June 2008 at The Hong Kong Club. A total of 28
editors and guests joined the Dinner. The Federation took the opportunity to express our sincere gratitude to all Issue
Editors and Dr. Walter King (Editor-in-Chief, 2004-2007) for their contribution for the Hong Kong Medical Diary.
Editor's Dinner
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Hong Kong Midwives Association
Hong Kong College of Anaesthesiologists (HKCA)
Our College is now 18 years old and now we feel that we should use our experience to help other neighbouring
countries establish their own uniform training and accreditation standards. Also with the knowledge that we have
gained in conference organisation with the Society of Anaesthetists of Hong Kong, we are planning to hold even
larger international scientific meetings and we will be sending a delegation to bid for the World Congress of
Anaesthesiologists to be held in 2016.
All the Boards and Committees have had another busy year and we have again organised clinical and basic science
courses for trainees that have been very well received. Simulation is an important part of training in professions
where critical incidents may occur infrequently but need to be rapidly and appropriately treated e.g. airlines,
power stations. Anaesthesia has been at the forefront of such developments in medical training and our Institute of
Clinical Simulation is now in the process of expansion with the appointment of a full time staff manager to
coordinate the courses and manage the facility. More instructors have been recruited from other disciplines and
medical specialties as well as developing overseas collaboration. Consequently a wide range of courses are now
being offered not just for anaesthetists. These courses are available to both trainees and specialists who wish to
refresh certain skills. As advanced human patient simulators become more widespread, it will not be surprising if
they eventually become an integral part of accreditation and it is important that we support this facility.
The Board of Intensive Care Medicine has introduced a 2 year training programme that is open to both HKCA and
College of Emergency Medicine trainees undergoing Higher Vocational training.
The Board of Pain Medicine will change the examination format next year to include an oral examination.
Hong Kong Midwives Association was established in 1967, originated from The Hong Kong Nurses and Midwives
Association which was founded in 1940. It is the only professional association for midwives in Hong Kong. We represent
Hong Kong SAR as the Member Association of International Confederation of Midwives. All the members are registered
midwives under the Midwives Registration Ordinance in Hong Kong. Up till now, our association has over 700 Full
Members. We also welcome other nursing professionals to join as Associate Members.
In Year 2000, we collaborated with the Obstetrical & Gynaecological Society of Hong
Kong to launch the Journal of Gynaecology, Obstetrics & Midwifery, the first of its
kind in Hong Kong and worldwide. In order to further enhance the training and
development of midwifery practice, as well as to focus more on standards for
midwifery practice, the association intends to establish a College of Midwives to
achieve the set goals in the near future.
You are cordially invited to browse
our website on http://midwives.org.hk and
get connected with us.
The aims of the association are as follows:
1) To protect and maintain the standards of midwifery practice in Hong Kong.
2) To explain and expound the laws and regulations of Hong Kong for the information
of midwives.
3) To make representation to the Government or any of its departments on any
questions or matters affecting the standards of midwifery in Hong Kong.
4) To promote and encourage unity and friendly relationship among midwives.
5) To advance and promote learning and education and to grant scholarships and
prizes.
In these regards, we shall:
1. Provide training and learning opportunities to
midwives.
2. Represent our profession in the Hong Kong Midwives
Council to govern the development and monitor the
standards of our practice.
3. Represent midwives of Hong Kong and participate as
member of the International Confederation of Midwives.
4. Provide education to the public with the view to
improve the public's awareness in health care during
pregnancy as well as baby care and promote breast feeding.
Midwife & Baby Care in the old days
Midwife & Parentcraft nowadays
Society's Message
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Date / Time Function Enquiry / Remarks
3 SUN
5
TUE
THU
Miss Viviane LAM
Tel: 2527 8452
(Registration Fee is required)
3 CME Points
HKMA Structured CME Programme at Queen Elizabeth Hospital Year 08/09
(V) - O&G and X-ray
Organised by: The Hong Kong Medical Association & Queen Elizabeth Hospital
Speaker: Dr. MA Wei Ling Teresa, Dr. LEE Chung Nin & Dr. WAI Man Wah
Andrew # Lecture Theatre, G/F., Block D, Queen Elizabeth Hospital, Kowloon
2:00 pm
Ms. June TSANG
Tel: 2527 8898 Fax: 2865 0345
Common Psychiatric Problems
Organised by: The Federation of Medical Societies of Hong Kong & The Hong
Kong College of Psychiatrists Speaker: Various # 4/F, Duke of Windsor Social
Service Building, Wanchai, Hong Kong
7:00 pm - 8:30 pm
7 Ms. Christine WONGTel: 2527 8285
HKMA Council Meeting
Organised by: The Hong Kong Medical Association Chairman: Dr. H.H. TSE #
HKMA Head Office, 5/F., Duke of Windsor Social Service Building, 15 Hennessy
Road, Hong Kong
8:00 pm
SUN10
MON11
Ms. Dora HO
Tel: 2527 8285
HKMA Trailwalker Training Session III (Stage 4 - 5)
Organised by: The Hong Kong Medical Association
8:00 pm
2:30 pm
SAT9
Ms. Phyllis KWOK
Fax: 2855 0947
3.5 CME Points
Colposcopy Workshop 2008
Organised by: The Hong Kong Society for Colposcopy & Cervical Pathology,
Department of O&G, Tuen Mun Hospital Chairman: Dr. S.M. CHAN Speaker:
Various # The Auditorium, 8/F, Southern Centre, 130 Hennessy Road, Wanchai,
Hong Kong
Ms. Clara TSANG
Tel: 2354 2440
Refresher Course for Health Care Providers 2007/2008 (XII) - Handling
Demented Patients in Primary Care
Organised by: The Hong Kong Medical Association & Our Lady of Maryknoll
Hospital # Training Room II, 1/F., OPD Block, Our Lady of Maryknoll Hospital,
118 Shatin Pass Road, Wong Tai Sin, Kowloon, Hong Kong
1:45 pm Miss Viviane LAM
Tel: 2527 8452
1 CME Point
HKMA - Shatin Community Network CME Lecture on Advances and Use of
Psychiatric Drugs in Primary Care
Organised by: HKMA - Shatin Community Network Chairman: Dr. Augustine
LAM Speaker: Dr. LAM Ho Bun # Royal Park Hotel, Shatin
TUE12
1:00 pm Miss Viviane LAM
Tel: 2527 8452
1 CME Point
HKMA CME - Hepatitis B - Treatment Goals
Organised by: The Hong Kong Medical Association Speaker: Dr. HU Hsing
Cheng Wayne # Metropolitan Restaurant, 438 King's Road, North Point, Hong
Kong
WED13
7:30 am Dr. Y.C. PO
Tel: 2990 3788 Fax: 2990 3789
2 CME Points
Hong Kong Neurosurgical Society Monthly Academic Meeting -
"Neuronavigation: The GPS of Neurosurgery"
Organised by: Hong Kong Neurosurgical Society Chairman: Dr. TAN Tze Ching
Speaker: Dr. LAU Chi Yan Jane # Seminar Room, G/F, Block A, Queen Elizabeth
Hospital, Kowloon
THU14
2:00 pm
3:00 pm
Miss Viviane LAM
Tel: 2527 8452
(Registration Fee is required)
1 CME Point
HKMA Structured CME Programme with Hong Kong Sanatorium & Hospital
Year 2008 (VIII)
Organised by: The Hong Kong Medical Association & Hong Kong Sanatorium &
Hospital Speaker: Dr. CHAN On On Annie # HKMA Dr. LI Shu Pui Professional
Education Centre, 2/F., Chinese Club Building, 21-22 Connaught Road Central,
Hong Kong
THU21
7:00 pm - 10:00 pm Ms. Paulina TANG
Tel: 2527 8898 Fax: 2865 0345
FMSHK Executive Committee Meeting & Council Meeting
Organised by: The Federation of Medical Societies of Hong Kong # Council
Chambers, 4/F., Duke of Windsor Social Service Building, 15 Hennessy Road,
Wanchai, Hong Kong
SAT23 Ms. Dora HOTel: 2527 8285HKMA Trailwalker Training Session IV (Stage 6 - 8)Organised by: The Hong Kong Medical Association
Ms. Paulina TANG
Tel: 2527 8898 Fax: 2865 0345
FMSHK Officers' Meeting
Organised by: The Federation of Medical Societies of Hong Kong # Gallop, 2/F.,
Hong Kong Jockey Club Club House, Shan Kwong Road, Happy Valley, Hong
Kong
8:00 pm - 10:00pm
9:00 am - 1:00pm
(19, 26)
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Calendar of Events
Meetings
3rd Regional Conference in Dermatological Laser and Facial Cosmetic Surgery 2008
Organised by: The Hong Kong Association of Specialists in Dermatology and The Hong Kong Society of Dermatology
and Venerology & Hong Kong Society of Plastic, Reconstructive and Aesthetic Surgeons # Hong Kong Convention and
Exhibition Centre, Wanchai, Hong Kong Enquiry: Ms. Ruby LUI Tel: 3151 8813 Fax: 2590 0099 Website:
www.dlfcs2008.com
26 - 28 /9/2008
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Meetings
2nd Asian Preventive Cardiology & Cardiac Rehabilitation Conference cum 7th Certificate Course in Cardiac
Rehabilitation
Organised by: Hong Kong College of Cardiology Co-Chairman: Prof. LAU Chu Pak & Dr. LAU Suet Ting Speaker:
Various # Hong Kong Convention & Exhibition Centre, 1 Expo Drive, Wanchai, Hong Kong Enquiry: Secretariat Tel:
2527 8285 Fax: 2865 0943 Email: dorahkma@hkma.org Website: http://www.apccrc.com
Human Dignity in Modern Medicine & 14th Congress of Asian Federation of Catholic Medical Associations
Organised by: The Guild of St. Luke, St. Cosmas and St. Damian Hong Kong Chairman: Dr. Peter AU YEUNG
Speaker: Prof. Fr Louis Aldrich SJ & Prof. Luke Gormally # Catholic Disease Centre Enquiry: Congress Secretariat Tel:
2363 0598 Fax: 3764 0579
CardioRhythm 2009
Organised by: Hong Kong College of Cardiology & Chinese Society of Pacing and Electrophysiology Co-Chairman:
Prof. LAU Chu Pak Enquiry: Secretariat Tel: 2899 2035 Fax: 2899 2045 Email: info@cardiorhythm.com Website:
http://www.cardiorhythm.com
22-25/11/2008
27-30/11/2008
20-22/2/2009
Courses
Certificate Course in "Health Promotion and Health Counselling" (Code No. TC-HPC-0801)
Organised by: College of Nursing, Hong Kong Enquiry: Secretariat
Tel: 2572 9255 Fax: 2838 6280 CNE Accreditation: 24 Points
Certificate Course in "Update in Orthopaedic Nursing" (Code No. TC-ON-0801)
Organised by: College of Nursing, Hong Kong Enquiry: Secretariat
Tel: 2572 9255 Fax: 2838 6280 CNE Accreditation: 24 Points
Certificate Course in "Interpretation of Electrocardiography" (Code No. TC-ECG-0801)
Organised by: College of Nursing, Hong Kong Enquiry: Secretariat
Tel: 2572 9255 Fax: 2838 6280 CNE Accreditation: 24 Points
Certificate Course in "Quality Management in Healthcare" (Code No. TC-QM-0801)
Organised by: College of Nursing, Hong Kong Enquiry: Secretariat
Tel: 2572 9255 Fax: 2838 6280 CNE Accreditation: 24 Points
1/9/2008 - 3/11/08
(Every Mon)
1/9/2008 - 3/11/08
(Every Mon)
5/9/2008 -
31/10/2008
(Every Fri)
5/9/2008 -
31/10/2008
(Every Fri)
Answer to Clinical Quiz
Consultant, Queen Mary Hospital
Dr. KS Tai
TIW hypointense and T2W hyperintense areas were seen at the L2-3 vertebrae. The L2-3 disc and adjacent end plates were also involved with
T2W hyperintense signal and loss of L2-3 disc height. Mild pre-, para- and epidural extension of lesion were also present. Mild focal spinal
stenosis was noted at L2-3 level with crowding of nerve roots. Areas of contrast enhancement were seen at these lesions, indicating active
disease.
Fusion of T12-Ll vertebral bodies seen with mild anterior wedge deformity. Mild posterior bulge with associated area of T2W hyperintense
signal was seen at mid posterior portion of the fused T12-Ll vertebral bodies mildly indenting the thecal sac. No significant compression of
the conus medullaris detected. Mild heterogeneous enhancement was seen at this region might represent residual inflammatory changes from
previous episode of spondylitis.
Bilateral psoas muscles were also involved which were swollen with contrast enhancement and T2W hyperintense signals. No obvious
drainable paraspinal abscess was detected.
Enhancing T2W hyperintense areas were also seen at the right ilium suggestive of active infection as well.
1.
2.
3.
4.
MRI findings:
Fluroscopic guided percutaneous bone biopsy of L2-3 vertebrae was performed. Histological examination of the tissue obtained showed acute
inflammatory changes. Culture revealed staphylococcus aureus. Patient was given appropriate antibiotic therapy.
Operative/histological findings:
Pyogenic infections of the spine involve primarily the disc space in children and the vertebral bodies in adults. Men are affected twice as often as
women and adults in the sixth and seventh decades are more commonly affected. The lumbar spine is most frequently involved. Predisposing factors
include diabetes, use of steroid or chemotherapy for cancer, immunological disease and IV drug abuse. Staphylococcus aureus accounts for 60% of
adult infections, while Escherichia coli, Pseudomonas aeruginosa and Klebsiella account for another 30%.
The patient's symptoms often precede the radiographic findings by several weeks. Culture of the disc material obtained by needle biopsy are negative
in 50-70% of patients.
The MRI findings of discitis and osteomyelitis closely match the pathological findings. The signal alternations reflect the early inflammatory response
characterised by infiltration of polymorphonuclear leukocytes and fibrin deposition in the adjacent end plates. Bony destruction secondary to lytic
enzymes and the associated increased water content are reflected by the increase T2W signal intensity and the decreased signal intensity on TIW
images. MRI is the most sensitive imaging technique to make the diagnosis. However the MRI findings may lag behind the clinical symptoms of back
pain. If the diagnosis is uncertain, a follow up MRI in a week may show the evolution of the early changes. Similarly the MRI findings may lag behind
the healing phase of vertebral osteomyelitis. Thus in the early stages of treatment, laboratory findings such as ESR and
white cell count are more helpful in monitoring the response to treatment than the MRI findings.
MRI is helpful in the detection of epidural extension of infective spondylodiscitis. The complete extent of involvement and the degree of cord
compression are both clearly delineated by MRI. Gadolinium is useful to distinguish epidural granulation tissue from a frank abscess. Epidural
granulation tissue enhances homogeneously while an epidural abscess will be enhanced at its periphery and contains non-enhancing pus in its centre.
This differentiation may be helpful in surgical planning.
The findings of healing osteomyelitis include persistent disc space narrowing, decreased T2W signal intensity of the disc consistent with disc
degeneration, fusion of adjacent vertebral bodies, and resolution of the high T2W signal intensity in the adjacent end plates corresponding to
resolution of the oedema. If an epidural abscess was present, the epidural space also returns to normal.
Discussion:

